Role of KEAP1/NRF2 and TP53 mutations in lung squamous cell carcinoma development and radiation resistance

Cancer Discovery

Volumn 7, Issue 1, 2017, Pages 86-101

  Jeong, Youngtae ^a,b   Hoang, Ngoc T ^a,b,c   Lovejoy, Alexander ^a,b   Stehr, Henning ^a   Newman, Aaron M ^b   Gentles, Andrew J ^b   Kong, William ^b   Truong, Diana ^a,b,d   Martin, Shanique ^b   Chaudhuri, Aadel ^b   Heiser, Diane ^b   Zhou, Li ^a   Say, Carmen ^b   Carter, Justin N ^b   Hiniker, Susan M ^b   Loo, Billy W ^a,b   West, Robert B ^b   Beachy, Philip ^b   Alizadeh, Ash A ^b   Diehn, Maximilian ^a,b  

^a STANFORD CANCER INSTITUTE   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c SAN FRANCISCO STATE UNIVERSITY   (United States)

^d SAN JOSE STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN 5; GLUTATHIONE; HISTONE H2AX; KELCH LIKE ECH ASSOCIATED PROTEIN 1; PROTEIN P53; TAMOXIFEN; TRANSCRIPTION FACTOR NRF2; KEAP1 PROTEIN, HUMAN; NFE2L2 PROTEIN, HUMAN; TP53 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INVASION ASSAY; CELL TRANSPLANTATION; CONTROLLED STUDY; EPITHELIUM BASAL CELL; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC TRANSDUCTION; GENOTYPE PHENOTYPE CORRELATION; GENOTYPING TECHNIQUE; HISTOLOGY; INCIDENCE; MOLECULAR BIOLOGY; MOUSE; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; RADIOSENSITIVITY; REAL TIME POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; SQUAMOUS CELL LUNG CARCINOMA; TREATMENT RESPONSE; TUMOR XENOGRAFT; ADULT; AGED; ANIMAL; CARCINOMA, SQUAMOUS CELL; CELL SELF-RENEWAL; CYTOLOGY; DISEASE MODEL; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PATHOLOGY; RADIATION TOLERANCE; STEM CELL; TRACHEA; TUMOR CELL CULTURE; TUMOR CELL LINE; TUMOR INVASION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL SELF RENEWAL; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KELCH-LIKE ECH-ASSOCIATED PROTEIN 1; LUNG NEOPLASMS; MALE; MICE; MIDDLE AGED; MUTATION; NEOPLASM INVASIVENESS; NF-E2-RELATED FACTOR 2; RADIATION TOLERANCE; STEM CELLS; TRACHEA; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 85009404026     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-16-0127     Document Type: Article

References (75)

1. Cancer.org [Internet]. Atlanta: American Cancer Society. Cancer Facts & Figures 2014; c2016. Available from: http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2014/
2. Xu C, Fillmore CM, Koyama S, Wu H, Zhao Y, Chen Z, et al. Loss of Lkb1 and Pten leads to lung squamous cell carcinoma with elevated PD-L1 expression. Cancer Cell 2014; 25: 590–604.
3. Xiao Z, Jiang Q, Willette-Brown J, Xi S, Zhu F, Burkett S, et al. The pivotal role of IKKalpha in the development of spontaneous lung squamous cell carcinomas. Cancer Cell 2013; 23: 527–40.
4. Mukhopadhyay A, Berrett KC, Kc U, Clair PM, Pop SM, Carr SR, et al. Sox2 cooperates with Lkb1 loss in a mouse model of squamous cell lung cancer. Cell Rep 2014; 8: 40–9.
5. Cancer Genome Atlas Research N. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012; 489: 519–25.
6. Itoh K, Chiba T, Takahashi S, Ishii T, Igarashi K, Katoh Y, et al. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun 1997; 236: 313–22.
7. Itoh K, Wakabayashi N, Katoh Y, Ishii T, Igarashi K, Engel J D, et al. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. Genes Dev 1999; 13: 76–86.
8. Kobayashi A, Kang MI, Okawa H, Ohtsuji M, Zenke Y, Chiba T, et al. Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2. Mol Cell Biol 2004; 24: 7130–9.
9. DeNicola GM, Karreth FA, Humpton TJ, Gopinathan A, Wei C, Frese K, et al. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 2011; 475: 106–9.
10. Satoh H, Moriguchi T, Takai J, Ebina M, Yamamoto M. Nrf2 prevents initiation but accelerates progression through the Kras signaling pathway during lung carcinogenesis. Cancer Res 2013; 73: 4158–68.
11. Yamadori T, Ishii Y, Homma S, Morishima Y, Kurishima K, Itoh K, et al. Molecular mechanisms for the regulation of Nrf2-mediated cell proliferation in non-small-cell lung cancers. Oncogene 2012; 31: 4768–77.
12. Sayin VI, Ibrahim MX, Larsson E, Nilsson JA, Lindahl P, Bergo MO. Antioxidants accelerate lung cancer progression in mice. Sci Transl Med 2014; 6: 221ra15.
13. Le Gal K, Ibrahim MX, Wiel C, Sayin VI, Akula MK, Karlsson C, et al. Antioxidants can increase melanoma metastasis in mice. Sci Transl Med 2015; 7: 308re8.
14. Bauer AK, Hill T 3rd, Alexander CM. The involvement of NRF2 in lung cancer. Oxid Med Cell Longev 2013; 2013: 746432.
15. Rock JR, Randell SH, Hogan BL. Airway basal stem cells: a perspective on their roles in epithelial homeostasis and remodeling. Dis Model Mech 2010; 3: 545–56.
16. Paul MK, Bisht B, Darmawan DO, Chiou R, Ha VL, Wallace WD, et al. Dynamic changes in intracellular ROS levels regulate airway basal stem cell homeostasis through Nrf2-dependent Notch signaling. Cell Stem Cell 2014; 15: 199-214.
17. DuPage M, Dooley AL, Jacks T. Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase. Nat Protoc 2009; 4: 1064–72.
18. Meuwissen R, Linn SC, Linnoila RI, Zevenhoven J, Mooi WJ, Berns A. Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model. Cancer Cell 2003; 4: 181–9.
19. Wang Y, Zhang Z, Yan Y, Lemon WJ, LaRegina M, Morrison C, et al. A chemically induced model for squamous cell carcinoma of the lung in mice: histopathology and strain susceptibility. Cancer Res 2004; 64: 1647–54.
20. Lijinsky W, Reuber MD. Neoplasms of the skin and other organs observed in Swiss mice treated with nitrosoalkylureas. J Cancer Res Clin Oncol 1988; 114: 245–9.
21. Lee JH, Bhang DH, Beede A, Huang TL, Stripp BR, Bloch KD, et al. Lung stem cell differentiation in mice directed by endothelial cells via a BMP4-NFATc1-thrombospondin-1 axis. Cell 2014; 156: 440–55.
22. Goldstein AS, Huang J, Guo C, Garraway IP, Witte ON. Identification of a cell of origin for human prostate cancer. Science 2010; 329: 568-71.
23. Liu K, Jiang M, Lu Y, Chen H, Sun J, Wu S, et al. S ox2 cooperates with inflammation-mediated Stat3 activation in the malignant transformation of foregut basal progenitor cells. Cell Stem Cell 2013; 12: 304-15.
24. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A 2005; 102: 15545–50.
25. Thu KL, Pikor LA, Chari R, Wilson IM, Macaulay CE, English JC, et al. Genetic disruption of KEAP1/CUL3 E3 ubiquitin ligase complex components is a key mechanism of NF-kappaB pathway activation in lung cancer. J Thorac Oncol 2011; 6: 1521–9.
26. Lee DF, Kuo HP, Liu M, Chou CK, Xia W, Du Y, et al. KEAP1 E3 ligase-mediated downregulation of NF-kappaB signaling by targeting IKKbeta. Mol Cell 2009; 36: 131–40.
27. Hall EJ, Giaccia AJ. Radiobiology for the radiologist. 7th ed. Philadelphia: Lippincottt Williams & Wilkins; 2011.
28. Lo M, Wang YZ, Gout PW. The x(c)-cystine/glutamate antiporter: a potential target for therapy of cancer and other diseases. J Cell Physiol 2008; 215: 593–602.
29. Huang Y, Dai Z, Barbacioru C, Sadee W. Cystine-glutamate transporter SLC7A11 in cancer chemosensitivity and chemoresistance. Cancer Res 2005; 65: 7446–54.
30. Yoshikawa M, Tsuchihashi K, Ishimoto T, Yae T, Motohara T, Sugihara E, et al. xCT inhibition depletes CD44v-expressing tumor cells that are resistant to EGFR-targeted therapy in head and neck squamous cell carcinoma. Cancer Res 2013; 73: 1855–66.
31. Ma MZ, Chen G, Wang P, Lu WH, Zhu CF, Song M, et al. Xc- inhibitor sulfasalazine sensitizes colorectal cancer to cisplatin by a GSHdependent mechanism. Cancer Lett 2015; 368: 88–96.
32. Thunnissen E, Kerr KM, Herth FJ, Lantuejoul S, Papotti M, Rintoul RC, et al. The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working group. Lung Cancer 2012; 76: 1–18.
33. Newman AM, Bratman SV, To J, Wynne JF, Eclov NC, Modlin LA, et al. An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med 2014; 20: 548–54.
34. Newman AM, Lovejoy AF, Klass DM, Kurtz DM, Chabon JJ, Scherer F, et al. Integrated digital error suppression for improved detection of circulating tumor DNA. Nat Biotechnol 2016; 34: 547–55.
35. Abazeed ME, Adams DJ, Hurov KE, Tamayo P, Creighton CJ, Sonkin D, et al. Integrative radiogenomic profiling of squamous cell lung cancer. Cancer Res 2013; 73: 6289–98.
36. Lee S, Lim MJ, Kim MH, Yu CH, Yun YS, Ahn J, et al. An effective strategy for increasing the radiosensitivity of Human lung Cancer cells by blocking Nrf2-dependent antioxidant responses. Free Radic Biol Med 2012; 53: 807–16.
37. Singh A, Bodas M, Wakabayashi N, Bunz F, Biswal S. Gain of Nrf2 function in non-small-cell lung cancer cells confers radioresistance. Antioxid Redox Signaling 2010; 13: 1627–37.
38. Cescon DW, She D, Sakashita S, Zhu CQ, Pintilie M, Shepherd FA, et al. NRF2 pathway activation and adjuvant chemotherapy benefit in lung squamous cell carcinoma. Clin Cancer Res 2015; 21: 2499–505.
39. Solis LM, Behrens C, Dong W, Suraokar M, Ozburn NC, Moran C A, et al. Nrf2 and Keap1 abnormalities in non–small cell lung carcinoma and association with clinicopathologic features. Clin Cancer Res 2010; 16: 3743–53.
40. Shibata T, Ohta T, Tong KI, Kokubu A, Odogawa R, Tsuta K, et al. Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy. Proc Natl Acad Sci U S A 2008; 105: 13568–73.
41. Shibata T, Kokubu A, Saito S, Narisawa-Saito M, Sasaki H, Aoyagi K, et al. NRF2 mutation confers malignant potential and resistance to chemoradiation therapy in advanced esophageal squamous cancer. Neoplasia 2011; 13: 864–73.
42. Borthwick DW, Shahbazian M, Krantz QT, Dorin JR, Randell SH. Evidence for stem-cell niches in the tracheal epithelium. Am J Respir Cell Mol Biol 2001; 24: 662–70.
43. Jackson EL, Olive KP, Tuveson DA, Bronson R, Crowley D, Brown M, et al. The differential effects of mutant p53 alleles on advanced murine lung cancer. Cancer Res 2005; 65: 10280–8.
44. Sutherland KD, Proost N, Brouns I, Adriaensen D, Song JY, Berns A. Cell of origin of small cell lung cancer: inactivation of Trp53 and Rb1 in distinct cell types of adult mouse lung. Cancer Cell 2011; 19: 754–64.
45. Tata PR, Mou H, Pardo-Saganta A, Zhao R, Prabhu M, Law BM, et al. Dedifferentiation of committed epithelial cells into stem cells in vivo. Nature 2013; 503: 218–23.
46. Zuo W, Zhang T, Wu DZ, Guan SP, Liew AA, Yamamoto Y, et al. p63(+)Krt5(+) distal airway stem cells are essential for lung regeneration. Nature 2015; 517: 616–20.
47. Gao Y, Zhang W, Han X, Li F, Wang X, Wang R, et al. YAP inhibits squamous transdifferentiation of Lkb1-deficient lung adenocarcinoma through ZEB2-dependent DNp63 repression. Nat Commun 2014; 5: 4629.
48. Han X, Li F, Fang Z, Gao Y, Li F, Fang R, et al. T ransdifferentiation of lung adenocarcinoma in mice with Lkb1 deficiency to squamous cell carcinoma. Nat Commun 2014; 5: 3261.
49. Li F, Han X, Li F, Wang R, Wang H, Gao Y, et al. LKB1 inactivation elicits a redox imbalance to modulate non–small cell lung cancer plasticity and therapeutic response. Cancer Cell 2015; 27: 698–711.
50. Xu X, Huang L, Futtner C, Schwab B, Rampersad RR, Lu Y, et al. The cell of origin and subtype of K-Ras-induced lung tumors are modified by Notch and Sox 2. Genes Dev 2014; 28: 1929-39.
51. Malkoski SP, Cleaver TG, Thompson JJ, Sutton WP, Haeger SM, Rodriguez KJ, et al. Role of PTEN in basal cell derived lung carcinogenesis. Mol Carcinog 2014; 53: 841–6.
52. Franklin WA, Gazdar AF, Haney J, Wistuba II, La Rosa FG, Kennedy T, et al. Widely dispersed p53 mutation in respiratory epithelium. A novel mechanism for field carcinogenesis. J Clin Invest 1997; 100: 2133–7.
53. Pipinikas CP, Kiropoulos TS, Teixeira VH, Brown JM, Varanou A, Falzon M, et al. Cell migration leads to spatially distinct but clonally related airway cancer precursors. Thorax 2014; 69: 548–57.
54. Cancer Genome Atlas Research N. Comprehensive molecular profiling of lung adenocarcinoma. Nature 2014; 511: 543–50.
55. Kim Y, Hammerman PS, Kim J, Yoon JA, Lee Y, Sun JM, et al. Integrative and comparative genomic analysis of lung squamous cell carcinomas in East Asian patients. J Clin Oncol 2014; 32: 121–8.
56. Ohta T, Iijima K, Miyamoto M, Nakahara I, Tanaka H, Ohtsuji M, et al. Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth. Cancer Res 2008; 68: 1303–9.
57. Suzuki T, Maher J, Yamamoto M. Select heterozygous Keap1 mutations have a dominant-negative effect on wild-type Keap1 in vivo. Cancer Res 2011; 71: 1700–9.
58. Wang R, An J, Ji F, Jiao H, Sun H, Zhou D. Hypermethylation of the Keap1 gene in human lung cancer cell lines and lung cancer tissues. Biochem Biophys Res Commun 2008; 373: 151–4.
59. Zhang P, Singh A, Yegnasubramanian S, Esopi D, Kombairaju P, Bodas M, et al. Loss of Kelch-like ECH-associated protein 1 function in prostate cancer cells causes chemoresistance and radioresistance and promotes tumor growth. Mol Cancer Ther 2010; 9: 336–46.
60. Muscarella LA, Parrella P, D’Alessandro V, la Torre A, Barbano R, Fontana A, et al. Frequent epigenetics inactivation of KEAP1 gene in non-small cell lung cancer. Epigenetics 2011; 6: 710–9.
61. Gao YB, Chen ZL, Li JG, Hu XD, Shi XJ, Sun ZM, et al. Genetic landscape of esophageal squamous cell carcinoma. Nat Genet 2014; 46: 1097–102.
62. Lin DC, Hao JJ, Nagata Y, Xu L, Shang L, Meng X, et al. Genomic and molecular characterization of esophageal squamous cell carcinoma. Nat Genet 2014; 46: 467–73.
63. Cancer Genome Atlas N. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 2015; 517: 576–82.
64. Ojesina AI, Lichtenstein L, Freeman SS, Pedamallu CS, Imaz- Rosshandler I, Pugh TJ, et al. Landscape of genomic alterations in cervical carcinomas. Nature 2014; 506: 371–5.
65. Cancer Genome Atlas Research N. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 2014; 507: 315–22.
66. You Y, Richer EJ, Huang T, Brody SL. Growth and differentiation of mouse tracheal epithelial cells: selection of a proliferative population. Am J Physiol Lung Cell Mol Physiol 2002; 283: L1315–21.
67. Dontu G, Abdallah WM, Foley JM, Jackson KW, Clarke MF, Kawamura MJ, et al. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev 2003; 17: 1253-70.
68. Lukacs RU, Goldstein AS, Lawson DA, Cheng D, Witte ON. Isolation, cultivation and characterization of adult murine prostate stem cells. Nat Protoc 2010; 5: 702–13.
69. Wakabayashi N, Shin S, Slocum SL, Agoston ES, Wakabayashi J, Kwak MK, et al. Regulation of notch1 signaling by nrf2: implications for tissue regeneration. Sci Signal 2010; 3: ra52.
70. Okawa H, Motohashi H, Kobayashi A, Aburatani H, Kensler TW, Yamamoto M. Hepatocyte-specific deletion of the keap1 gene activates Nrf2 and confers potent resistance against acute drug toxicity. Biochem Biophys Res Commun 2006; 339: 79–88.
71. Madisen L, Zwingman TA, Sunkin SM, Oh SW, Zariwala HA, Gu H, et al. A robust and high-throughput Cre reporting and characterization system for the whole mouse brain. Nat Neurosci 2010; 13: 133–40.
72. Jonkers J, Meuwissen R, van der Gulden H, Peterse H, van der Valk M, Berns A. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat Genet 2001; 29: 418-25.
73. Rawlins EL, Ostrowski LE, Randell SH, Hogan BL. Lung development and repair: contribution of the ciliated lineage. Proc Natl Acad Sci U S A 2007; 104: 410–7.
74. Trakul N, Chang CN, Harris J, Chapman C, Rao A, Shen J, et al. Tumor volume-adapted dosing in stereotactic ablative radiotherapy of lung tumors. Int J Radiat Oncol Biol Phys 2012; 84: 231–7.
75. Schaffer BE, Park KS, Yiu G, Conklin JF, Lin C, Burkhart D L, et al. Loss of p130 accelerates tumor development in a mouse model for human small-cell lung carcinoma. Cancer Res 2010; 70: 3877–83.